SEC. ___. NATIONAL CENTER OF EXCELLENCE IN ADVANCED PHARMACEUTICAL MANUFACTURING.

(a) SHORT TITLE.—This section may be cited as the ''Securing America's Medicine Cabinet Act'' or the ''SAM–C Act''.

(b) AMENDMENT.—Chapter X of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 391 et seq.) is amended by adding at the end the following:

''SEC. 1015. NATIONAL CENTER OF EXCELLENCE IN ADVANCED PHARMACEUTICAL MANUFACTURING.

''(a) IN GENERAL.—The Secretary shall designate 5 institutions of higher education as National Centers of Excellence in Advanced Pharmaceutical Manufacturing, including continuous pharmaceutical manufacturing.

''(b) PURPOSES.—The purposes of the program under this section are to—

''(1) improve the competitiveness of domestic pharmaceutical manufacturing and increase the production of pharmaceutical goods manufactured predominantly within the United States;

''(2) stimulate United States leadership in advanced pharmaceutical manufacturing research, innovation, and technology;

''(3) facilitate the transition of innovative technologies into scalable, cost-effective, and high-performing manufacturing capabilities;

''(4) accelerate the development of an advanced pharmaceutical manufacturing workforce;

''(5) facilitate peer exchange of, and the documentation of, best practices in addressing advanced manufacturing challenges;

''(6) leverage non-Federal sources of support to promote a stable and sustainable business model without the need for long-term Federal funding; and

''(7) create and preserve jobs in the United States.

''(c) ELIGIBILITY.—To be eligible for designation under subsection (a) an entity shall—

''(1) be an institution of higher education;

''(2) demonstrate—

''(A) the physical and technical capacity for research and development of advanced pharmaceutical manufacturing;

''(B) a record of transferring scientific knowledge to the marketplace;

''(C) scalable manufacturing knowledge, which may be through collaborations of other institutions of higher education, biopharmaceutical manufacturers, or other entities;

''(D) the ability to train a future workforce for research on and implementation of advanced pharmaceutical manufacturing;

''(E) the ability to support Federal agencies with technical assistance for advanced pharmaceutical technologies, with an emphasis on creating a secure national pharmaceutical stockpile and the ability to rapidly address drug shortages; and

''(F) the potential to—

''(i) improve the competitiveness of domestic manufacturing;

''(ii) accelerate non-Federal investment in advanced manufacturing production capacity in the United States; and

''(iii) enable the commercial application of new technologies or industry-wide manufacturing processes;

''(3) agree to carry out the activities described in subsection (d) with the active participation of representatives from multiple industrial entities, research universities, community colleges, and such other entities as the Secretary determines appropriate; and

''(4) submit an application to the Secretary at such time, in such form, and in such manner as the Secretary may require.

''(d) ACTIVITIES.—An entity designated under subsection (a) shall—

''(1) assist pharmaceutical manufacturers in retaining or expanding industrial production and jobs in the United States;

''(2) conduct research, development, and demonstration projects, including proof-of-concept development and prototyping, to reduce the cost, time, and risk of commercializing new technologies and improvements in existing technologies, processes, products, and research and development of materials to solve precompetitive industrial problems with economic or national security implications; and

''(3) develop and implement education, training, and workforce recruitment courses, materials, and programs with respect to pharmaceutical manufacturing.

''(e) TERMINATION.—The Secretary may terminate the designation of an entity designated under subsection (a) upon a determination that the entity no longer meets the requirements of subsection (c).

''(f) ANNUAL REPORT.—Not later than 1 year after the date on which the first designation is made under subsection (a), and annually thereafter, the Secretary shall submit a report to Congress on the activities of the entities designated under such subsection.

''(g) ADVANCED MANUFACTURING.—In this section, the term 'advanced manufacturing' means pharmaceutical product development and manufacturing that incorporates novel technology or uses an established technique or technology in a new or innovative way that can improve pharmaceutical product quality, address shortages of medicines, and speed time-to-market.

''(h) AUTHORIZATION OF APPROPRIATIONS.—To carry out this section, there are authorized to be appropriated $100,000,000 for the period of fiscal year 2021 through 2025.''.

SA 2646. Mr. CORNYN submitted an amendment intended to be proposed to amendment SA 2499 proposed by Mr. MCCONNELL to the bill S. 178, to condemn gross human rights violations of ethnic Turkic Muslims in Xinjiang, and calling for an end to arbitrary detention, torture, and harassment of these communities inside and outside China; which was ordered to lie on the table; as follows:

At the appropriate place, insert the following:

SEC. _____. CLARIFICATION OF TREATMENT OF BUSINESS EXPENSES.

(a) IN GENERAL.—Subsection (i) of section 1106 of the CARES Act (Public Law 116–136) is amended—

(1) by striking ''1986, any amount'' and inserting ''1986—

''(1) any amount'',

(2) by striking the period at the end and inserting '', and'', and

(3) by adding at the end the following new paragraph:

''(2) no deduction shall be denied or reduced, no tax attribute shall be reduced, and no basis increase shall be denied, by reason of the exclusion from gross income provided by paragraph (1).''.

(b) EFFECTIVE DATE.—The amendments made by this section shall apply as if included in the enactment of section 1106 of the CARES Act (Public Law 116–136).

SA 2647. Mr. MCCONNELL (for Ms. DUCKWORTH) proposed an amendment to the bill S. 1014, to establish the Route 66 Centennial Commission, and for other purposes; as follows:

Strike all after the enacting clause and insert the following:

SECTION 1. SHORT TITLE.

This Act may be cited as the ''Route 66 Centennial Commission Act''.

SEC. 2. FINDINGS.

Congress finds that—

(1) Route 66 was the first all-weather highway in the United States connecting the Midwest to California, and has played a major role in the history of the United States;

(2) Route 66 has become a symbol of the heritage of travel and the legacy of seeking a better life shared by the people of the United States, and has been enshrined in the popular culture of the United States; and

(3) the year 2026 will be the centennial anniversary of Route 66, and a commission should be established to study and recommend in a report to Congress activities that are fitting and proper to celebrate that anniversary in a manner that appropriately honors the Mother Road of the United States.

SEC. 3. ESTABLISHMENT.

There is established a commission to be known as the ''Route 66 Centennial Commission'' (referred to in this Act as the ''Commission'').

SEC. 4. DUTIES.

The Commission shall—

(1) study activities that may be carried out by the Federal Government to determine whether the activities are fitting and proper to honor Route 66 on the occasion of the centennial anniversary of Route 66, including activities such as—

(A) the issuance of commemorative coins, medals, certificates of recognition, and postage stamps;

(B) ceremonies and celebrations commemorating specific events; and

(C) the production, publication, and distribution of books, pamphlets, films, electronic publications, and other educational materials; and

(2) recommend to Congress—

(A) the activities that the Commission considers most fitting and proper to honor Route 66 on the occasion described in paragraph (1); and

(B) 1 or more entities in the Federal Government that the Commission considers most appropriate to carry out those activities.

SEC. 5. MEMBERSHIP.

(a) NUMBER AND APPOINTMENT.—The Commission shall be composed of 15 members appointed as follows:

(1) 3 members, each of whom shall be an eligible individual described in subsection (b), appointed by the President based on the recommendation of the Secretary of Transportation.

(2) 1 member, who shall be an eligible individual described in subsection (b), appointed by the President based on the recommendation of the Governor of Illinois.

(3) 1 member, who shall be an eligible individual described in subsection (b), appointed by the President based on the recommendation of the Governor of Missouri.

(4) 1 member, who shall be an eligible individual described in subsection (b), appointed by the President based on the recommendation of the Governor of Kansas.

(5) 1 member, who shall be an eligible individual described in subsection (b), appointed by the President based on the recommendation of the Governor of Oklahoma.

(6) 1 member, who shall be an eligible individual described in subsection (b), appointed by the President based on the recommendation of the Governor of Texas.

(7) 1 member, who shall be an eligible individual described in subsection (b), appointed by the President based on the recommendation of the Governor of New Mexico.